3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
81
Dermatologic
48
Thoracic
47
Gastrointestinal
35
Genitourinary
19
Tumor-Agnostic
17
Sarcoma
17
Gynecologic
17
Breast
14
Lymphoid
7
CNS
4
Other
2
Other solid neoplasm
1
Other neoplasm
1
Endocrine
1
Conditions
Advanced Solid Tumors
432
Advanced Solid Tumor
352
Solid Tumor
305
Solid Tumors
246
Mesothelioma
115
Solid Tumor, Adult
76
Mesothelioma, Malignant
72
Carcinoma, Non-Small-Cell Lung
66
Ovarian Neoplasms
47
Melanoma
42
Carcinoma, Renal Cell
37
Colorectal Neoplasms
34
Advanced or Metastatic Solid Tumors
32
Uterine Cervical Neoplasms
31
Stomach Neoplasms
31
Solid Tumours
31
Esophageal Neoplasms
30
Neoplasms
27
Pancreatic Neoplasms
26
Squamous Cell Carcinoma of Head and Neck
25
Breast Neoplasms
25
Advanced Malignant Solid Tumors
25
Triple Negative Breast Neoplasms
24
Lung Neoplasms
24
Small Cell Lung Carcinoma
23
Advanced Solid Tumours
23
Sarcoma
21
Neoplasm Metastasis
21
Advanced Malignant Solid Tumor
21
Locally Advanced or Metastatic Solid Tumors
20
Interventions
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Squamous Cell
×
Other solid neoplasm
×
Clear all
NCT06444815
2026-04-07
STEALTH-001
KaliVir Immunotherapeutics
Phase 1
Recruiting
60 enrolled